Literature DB >> 25700421

Removing a hair of doubt about BRAF targeting.

Robert J Kreitman1.   

Abstract

In this issue of Blood, Pettirossi et al, including Drs Tiacci and Falini, who led the effort in 2011 defining the BRAF-V600E driving mutation in hairy cell leukemia (HCL),provide extensive laboratory studies showing that inhibitors of BRAF-V600E and/or mitogen-activated protein kinase kinase (MEK) reach their targets and cause HCL cell death

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25700421      PMCID： PMC4335076          DOI： 10.1182/blood-2014-12-616318

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  10 in total

1.  Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.

Authors:  Liqiang Xi; Evgeny Arons; Winnifred Navarro; Katherine R Calvo; Maryalice Stetler-Stevenson; Mark Raffeld; Robert J Kreitman
Journal:  Blood       Date:  2011-12-30       Impact factor: 22.113

2.  BRAF inhibition in refractory hairy-cell leukemia.

Authors:  Sascha Dietrich; Hanno Glimm; Mindaugas Andrulis; Christof von Kalle; Anthony D Ho; Thorsten Zenz
Journal:  N Engl J Med       Date:  2012-05-24       Impact factor: 91.245

3.  Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib.

Authors:  George A Follows; Hannah Sims; David M Bloxham; Thorsten Zenz; Melanie A Hopper; Hongxiang Liu; Anthony Bench; Penny Wright; Mars B Van't Veer; Mike A Scott
Journal:  Br J Haematol       Date:  2012-12-29       Impact factor: 6.998

4.  Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity?

Authors:  Preetesh Jain; Chi Young Ok; Sergej Konoplev; Keyur P Patel; Jeffrey Jorgensen; Zeev Estrov; Raja Luthra; Hagop Kantarjian; Farhad Ravandi
Journal:  J Clin Oncol       Date:  2014-06-30       Impact factor: 44.544

5.  BRAF mutations in hairy-cell leukemia.

Authors:  Enrico Tiacci; Vladimir Trifonov; Gianluca Schiavoni; Antony Holmes; Wolfgang Kern; Maria Paola Martelli; Alessandra Pucciarini; Barbara Bigerna; Roberta Pacini; Victoria A Wells; Paolo Sportoletti; Valentina Pettirossi; Roberta Mannucci; Oliver Elliott; Arcangelo Liso; Achille Ambrosetti; Alessandro Pulsoni; Francesco Forconi; Livio Trentin; Gianpietro Semenzato; Giorgio Inghirami; Monia Capponi; Francesco Di Raimondo; Caterina Patti; Luca Arcaini; Pellegrino Musto; Stefano Pileri; Claudia Haferlach; Susanne Schnittger; Giovanni Pizzolo; Robin Foà; Laurent Farinelli; Torsten Haferlach; Laura Pasqualucci; Raul Rabadan; Brunangelo Falini
Journal:  N Engl J Med       Date:  2011-06-11       Impact factor: 91.245

6.  Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia.

Authors:  Farhad Ravandi; Susan O'Brien; Jeffrey Jorgensen; Sherry Pierce; Stefan Faderl; Alessandra Ferrajoli; Charles Koller; Pramoda Challagundla; Sergernne York; Mark Brandt; Rajyalakshmi Luthra; Jan Burger; Deborah Thomas; Michael Keating; Hagop Kantarjian
Journal:  Blood       Date:  2011-08-05       Impact factor: 22.113

Review 7.  Hairy cell leukemia-new genes, new targets.

Authors:  Robert J Kreitman
Journal:  Curr Hematol Malig Rep       Date:  2013-09       Impact factor: 3.952

8.  Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia.

Authors:  Stephen S Chung; Eunhee Kim; Jae H Park; Christopher Y Park; Omar Abdel-Wahab; Young Rock Chung; Piro Lito; Julie Teruya-Feldstein; Wenhuo Hu; Wendy Beguelin; Sebastien Monette; Cihangir Duy; Raajit Rampal; Leon Telis; Minal Patel; Min Kyung Kim; Kety Huberman; Nancy Bouvier; Michael F Berger; Ari M Melnick; Neal Rosen; Martin S Tallman
Journal:  Sci Transl Med       Date:  2014-05-28       Impact factor: 17.956

9.  BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.

Authors:  Valentina Pettirossi; Alessia Santi; Elisa Imperi; Guido Russo; Alessandra Pucciarini; Barbara Bigerna; Gianluca Schiavoni; Elisabetta Fortini; Ariele Spanhol-Rosseto; Paolo Sportoletti; Roberta Mannucci; Maria Paola Martelli; Ludger Klein-Hitpass; Brunangelo Falini; Enrico Tiacci
Journal:  Blood       Date:  2014-12-05       Impact factor: 22.113

10.  High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias.

Authors:  Joshua J Waterfall; Evgeny Arons; Robert L Walker; Marbin Pineda; Laura Roth; J Keith Killian; Ogan D Abaan; Sean R Davis; Robert J Kreitman; Paul S Meltzer
Journal:  Nat Genet       Date:  2013-11-17       Impact factor: 38.330
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.